Predicting the Onset of Nonlinear Pharmacokinetics
Author:
Affiliation:
1. Novartis Institute for BioMedical Research; Cambridge MA USA
2. Mathematical Institute; Leiden University; RA Leiden The Netherlands
Publisher
Wiley
Subject
Pharmacology (medical),Modeling and Simulation
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1002/psp4.12316/fullpdf
Reference12 articles.
1. Population pharmacokinetics and pharmacodynamics of the anti-CD11a antibody hu1124 in human subjects with psoriasis;Bauer;J. Pharmacokinet. Biopharm.,1999
2. Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study;Burmester;Ann. Rheum. Dis.,2011
3. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody;Padhi;J. Bone Miner. Res.,2011
4. Incorporating target-mediated drug disposition in a minimal physiologically-based pharmacokinetic model for monoclonal antibodies;Cao;J. Pharmacokinet Pharmacodyn.,2014
5. The kinetics of the inversion effect;Michaelis;Biochem. Z.,1913
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Sabatolimab (MBG453) model‐informed drug development for dose selection in patients with myelodysplastic syndrome/acute myeloid leukemia and solid tumors;CPT: Pharmacometrics & Systems Pharmacology;2023-05-31
2. The quest for balance between capturing data and model complexity: A quantitative clinical pharmacology approach applied to monoclonal antibodies;CPT: Pharmacometrics & Systems Pharmacology;2023-03-23
3. A mechanistic PK/PD model to enable dose selection of the potent anti‐tryptase antibody (MTPS9579A) in patients with moderate‐to‐severe asthma;Clinical and Translational Science;2023-02-08
4. Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration;Frontiers in Oncology;2023-01-11
5. Early Feasibility Assessment: A Method for Accurately Predicting Biotherapeutic Dosing to Inform Early Drug Discovery Decisions;Frontiers in Pharmacology;2022-06-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3